The InsuJet is developed, manufactured and sold by a small team of dedicated people who believe in a needle-free future for patients with chronic conditions such as diabetes. The legal manufacturer of the InsuJet is located in the Netherlands, and has offices in Asia and North America to ensure the technology becomes available to patients in need of needle-free alternatives around the world.
Albania, Andorra, Armenia, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Croatia, Cyprus, Czech Republic (Czechia), Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Italy, Jordan, Latvia, Liechtenstein, Lithuania, Luxembourg, Macao, Malaysia, Malta, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Qatar, Romania, San Marino, Saudi Arabia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, United Arab Emirates, United Kingdom.
The InsuJet will be launched in Romania in September 2023. This will be announced shortly on the website of our distributor:
Strada Popa Savu nr 66, sector 1, Bucuresti
The InsuJet community and medical professionals turn our scientific and medical discoveries into solutions for their life.
Meet the InsuJet Team
InsuJet has been in development for over two decades. We have been gathering clinical data and market feedback, for over a decade. At this stage we are confident that we are in a position to revolutionize the entire needle-free market.
Used needles are a massive environmental concern. In the US alone, 7.8 bilion needles are disposed of on an annual basis, and most are for insulin use.
To fight this, we must push back on the use of single-use disposables. For every InsuJet user, we eliminate more than 1000 needles per year! That saves a lot of biohazardous waste and the added environmental cost of its collection.
In many countries where needles are not properly collected and disposed off. The elimination of single-use disposables helps to protect our environment.
01. Compatible insulin types: Human and animal; Fast acting insulins (bolus); Rapid Acting Insulin Analogs; Regular Human Insulin; Basal insulins; Intermediate-acting, commonly: NPH/ Isophane; Long-acting, commonly: Glargine, detemir, degludec; Premixtures (e.g. 30/70).
02. In a user survey, 78% of respondents answered they would recommend InsuJet™ to others.
03. In a user survey, 40% of the respondents answered they noticed using less insulin.
04. Needle-Free Jet Injection of Rapid-Acting Insulin Improves Early Postprandial Glucose Control in Patients With Diabetes. Diabetes Care, October 2013.
05. Body mass index and the efficacy of needle-free jet injection for the administration of rapid-acting insulin analogs, a post hoc analysis. Diabetes, Obesity and Metabolism, July 2012.
06. Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology. Diabetes Care, August 2011
07. A Pilot Study to Examine the Tolerability and Device Preference in Type 1 Diabetes of Insulin Apart Administered by InsuJet™ Compared with Subcutaneous Injection. Diabetes Technology & Therapeutics, 2014.
08. See medical deck Cost Analysis - North America, 2022 available on the Partner page.
09. Calculated at 4 injections a day with a hypodermic needle. 4 injection a day, every day of the year, adds up to 1,460 needles a year saved from use.
*. The InsuJet™ is calibrated for U-100 insulins
**. Needle gauge 26-27 is commonly used for subcutaneous injections and is around 0.40 - 0.45mm in diameter. The orifice of the InsuJet™ Nozzle is about 0.15mm in diameter which is much smaller than conventional needle gauges used for subcutaneous insulin injections.
***. https://pubmed.ncbi.nlm.nih.gov PMID:18820853